Idexx Laboratories INC /DE Form 4 insider transactions

IDEXX Laboratories President and CEO, Jonathan Jay Mazelsky, gifted 1,051 shares of common stock.

IDEXX Laboratories Executive Vice President Martin A. Smith reported the acquisition of 18 shares through RSU vesting and the disposition of 5 shares for tax purposes.

IDEXX Laboratories Director Joseph L. Hooley was granted 158 restricted stock units and 364 non-qualified stock options as pro rata equity compensation.

An IDEXX Laboratories director exercised stock options and sold a portion of the resulting shares, while also gifting shares to a family foundation.

IDEXX Laboratories Executive Vice President Michael G. Erickson sold 405.892 shares of common stock for approximately $263,770 under a pre-arranged Rule 10b5-1 plan.

IDEXX Executive Vice President Nimrata Hunt reported a sale of common stock alongside the exercise of multiple stock options, resulting in a net increase in direct beneficial ownership as part of a pre-planned Rule 10b5-1 arrangement.

IDEXX Laboratories' EVP, GC & Corporate Secretary, Sharon E. Underberg, reported exercising stock options and selling shares in August 2025.

IDEXX Laboratories CEO Jonathan Mazelsky exercised options to acquire 183 shares of common stock at $598.488 per share.

IDEXX Laboratories' EVP, CFO, and Treasurer, Andrew Emerson, exercised stock options and subsequently sold a portion of the acquired shares.

IDEXX Laboratories Executive Vice President Nimrata Hunt increased her direct beneficial ownership by 5,651 shares after exercising stock options and selling a portion of the acquired shares.

IDEXX Laboratories' President and CEO, Jonathan Jay Mazelsky, exercised stock options and simultaneously sold an equivalent number of shares.

IDEXX Executive Vice President Michael Lane exercised stock options and subsequently sold a portion of his common stock holdings on August 6, 2025.

IDEXX Laboratories Executive Vice President Michael P. Johnson reported the vesting of 3,382 restricted stock units and the subsequent disposition of 1,499 shares for tax withholding, alongside an acquisition of 3,382 shares, resulting in a net beneficial ownership of 2,365.3419 common shares.

IDEXX Laboratories Director M. Anne Szostak exercised stock options and sold a total of 2,306 shares of common stock for over $1.18 million on May 21, 2025.

Director Daniel M. Junius reports exercising stock options and selling shares of IDEXX Laboratories on May 13, 2025.

Director Sophie V. Vandebroek reports exercising stock options and selling shares of IDEXX Laboratories, Inc.

Director Sophie V. Vandebroek reports transactions involving IDEXX Laboratories stock, including the vesting of restricted stock units and the grant of stock options.

M. Anne Szostak, a director at IDEXX Laboratories, reported the vesting of restricted stock units and the grant of stock options.

Director Sam Samad reports acquisition of stock options and deferred stock units in IDEXX Laboratories.

Director Lawrence D. Kingsley reports transactions involving IDEXX Laboratories stock, including the acquisition of common stock and derivative securities.

Director Daniel M. Junius reports acquisition and disposal of IDEXX Laboratories stock and derivative securities.

Director Stuart Essig reports acquisition and disposal of IDEXX Laboratories stock and derivative securities.

Bruce L. Claflin, a director of IDEXX Laboratories, reported the acquisition of stock options and deferred stock units.

Director Irene Chang Britt acquired stock options and deferred stock units in IDEXX Laboratories, according to a recent SEC filing.

Brian P. McKeon, EVP, CFO and Treasurer of IDEXX Laboratories, reports transactions involving common stock and restricted stock units on February 14, 2025.

Sharon E. Underberg, EVP, GC & Corporate Secretary of IDEXX Laboratories, reports acquisition and disposal of common stock and derivative securities.

Executive Vice President Martin Alexander Smith reports the grant of stock options and vesting of restricted stock units (RSUs) in IDEXX Laboratories Inc.

Executive Vice President Michael Schreck of IDEXX Laboratories reports the grant of stock options and vesting of restricted stock units (RSUs) in a recent SEC filing.

Jonathan Mazelsky, President and CEO of IDEXX Laboratories, reports the acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, in recent transactions.

Executive Vice President Michael Lane of IDEXX Laboratories reports transactions involving common stock and derivative securities, including stock options and restricted stock units.